Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)

NCT03212989 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: Vorinostat
BIOLOGICAL: HXTC

Sponsor

University of North Carolina, Chapel Hill

Collaborators

[object Object]